EXAC Exactech, Inc.

Exactech Announces Successful First Surgeries with New Equinoxe® Preserve Stem and ExactechGPS® Shoulder Application

Exactech, Inc. (Nasdaq: EXAC), a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today a successful first surgery using the new Equinoxe® Preserve stem, a conservative shoulder treatment option designed to preserve humeral bone in shoulder replacement surgery. Additionally, surgeons performed the first U.S. procedures using the ExactechGPS® Shoulder Application.

Orthopaedic surgeon Thomas Wright, MD, performed the first Preserve stem surgery in Gainesville, Fla. “The surgical team and I were pleased with the results of today’s surgery, including the thoughtful implant design, practical instrumentation and relatively simple technique,” Dr. Wright said.

The Preserve stem expands the options offered by the successful Equinoxe® Platform Shoulder System. This new stem is approximately two-thirds the length of the system’s current stem.

“Creating a bone preserving stem that can be used alongside already clinically successful components of our Equinoxe anatomic and reverse implants is an important evolutionary step in our perpetual pursuit of improved clinical outcomes,” said Darin Johnson, Vice President of Marketing, Extremities.

The implant design was developed through the use of CT reconstruction data and clinical studies. Specifically, the implant features a unique polished distal tip to facilitate any need for removal, a straight lateral fin designed for greater rotational stability and plasma coating to aid proximal fixation.

“The technique and implant were created to provide a more bone preserving option within the Equinoxe suite. It was a great pleasure over the last couple of years to collaborate with Drs. Samuel Antuna, Ken Faber, Howard Routman, Joseph Zuckerman and Pierre-Henri Flurin on this innovative improvement. This product demonstrates Exactech’s commitment to working closely with surgeons to improve patient outcomes,” Dr. Wright said.

Dr. Wright and Richard Jones, MD, of Asheville, N.C., also completed the first U.S. surgeries using the ExactechGPS Shoulder Application, a computer-assisted shoulder arthroplasty technology. “This advance in shoulder arthroplasty - being able to execute a preoperative plan in the operating room with real-time visibility into the glenoid vault - has almost limitless possibilities to help patients. Ten years ago, Dr. Sean Grey and I implanted the first Equinoxe reverse shoulder, and that innovation set the pace for the last decade. Now, I believe, ExactechGPS is the breakthrough for the next decade,” Dr. Jones said.

Full U.S. market availability for the Preserve Stem and ExactechGPS Shoulder Application is planned for the beginning of 2018.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

A current investment profile on Exactech (Nasdaq: EXAC) is available online at http://www.hawkassociates.com/profile/exac.cfm. To receive future releases in e-mail alerts, sign up at http://www.hawkassociates.com/about/alert.

This release contains various forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, which represent the company’s expectations or beliefs concerning future events of the company’s financial performance. These forward-looking statements are further qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. These factors include the effect of competitive pricing, the company’s dependence on the ability of third party manufacturers to produce components on a basis which is cost-effective to the company, market acceptance of the company’s products and the effects of government regulation. Results actually achieved may differ materially from expected results included in these statements.

EN
06/06/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Exactech, Inc.

 PRESS RELEASE

Exactech Announces Completion of Merger with TPG Capital

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech, Inc. (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, is pleased to announce the successful completion of the previously announced merger agreement with TPG Capital, pursuant to which TPG has acquired all of the issued and outstanding common stock of Exactech. In connection with the transaction, Exactech shareholders will receive $49.25 in cash for each share of Exactech common stock they hold (o...

 PRESS RELEASE

Exactech Shareholders Approve Merger Agreement with TPG Capital

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech (Nasdaq: EXAC), a leading developer and producer of orthopaedic implant devices and surgical instrumentation for extremities and large joints, today announced that at a Special Meeting of Shareholders held earlier today, Exactech’s shareholders approved the previously announced merger agreement with TPG Capital and certain of its affiliates, and approved the other two proposals described in Exactech’s proxy statement relating to today’s meeting. Approximately 94.5% of voting Exact...

 PRESS RELEASE

EXACTECH (EXAC) INVESTOR ALERT - Andrews & Springer LLC is Seeking Mor...

WILMINGTON, Del.--(BUSINESS WIRE)-- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Exactech, Inc. (NASDAQGS: EXAC) (“Exactech” or the “Company”) relating to the sale of the Company to affiliates of private equity firm TPG Capital (“TPG”). On December 4, 2017, the two parties announced the signing of an amended merger agreement pursuant to which TPG will acquire Exacte...

 PRESS RELEASE

EXACTECH (EXAC) SHAREHOLDER ALERT - Andrews & Springer LLC is Seeking ...

WILMINGTON, Del.--(BUSINESS WIRE)-- Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Exactech, Inc. (NASDAQGS: EXAC) (“Exactech” or the “Company”) relating to the sale of the Company to affiliates of private equity firm TPG Capital (“TPG”). On December 4, 2017, the two parties announced the signing of an amended merger agreement pursuant to which TPG will acquire Exacte...

 PRESS RELEASE

Exactech Announces Successful First Surgery with Vantage ® Total Ankl...

GAINESVILLE, Fla.--(BUSINESS WIRE)-- Exactech, Inc. (Nasdaq:EXAC), a developer and producer of bone and joint restoration products for extremities, hip, and knee, announced today the successful first surgery using its new Vantage® Total Ankle Mobile Bearing System, the newest addition to the Exactech extremities product line. Orthopaedic surgeon and Vantage Ankle design team member Professor Victor Valderrabano, MD, PhD, chairman of the Swiss Ortho Center Basel, recently performed the first case in the world with the mobile, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch